These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15538901)

  • 1. [Mortality and survival in a cohort of 1,115 HIV-infected patients (1989-97)].
    San Andrés Rebollo FJ; Rubio García R; Castilla Catalán J; Pulido Ortega F; Palao G; de Pedro Andrés I; Costa Pérez-Herrero JR; del Palacio Pérez-Medel A
    An Med Interna; 2004 Nov; 21(11):523-32. PubMed ID: 15538901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.
    Eldred LJ; Wu AW; Chaisson RE; Moore RD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):117-25. PubMed ID: 9637576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of antiretroviral treatment and prophylaxis for opportunistic infections on survival of patients with AIDS].
    Gálvez Hermoso C; Blanco Quintana F; del Amo Valero J; Díez Ruiz-Navarro M; Soriano Vázquez V; González Lahoz J
    Rev Clin Esp; 2000 Apr; 200(4):187-92. PubMed ID: 10857401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.
    Alvarez-Martínez MJ; Moreno A; Miró JM; Valls ME; Rivas PV; de Lazzari E; Sued O; Benito N; Domingo P; Ribera E; Santín M; Sirera G; Segura F; Vidal F; Rodríguez F; Riera M; Cordero ME; Arribas JR; Jiménez de Anta MT; Gatell JM; Wilson PE; Meshnick SR;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):34-43. PubMed ID: 18554841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.
    Walzer PD; Evans HE; Copas AJ; Edwards SG; Grant AD; Miller RF
    Clin Infect Dis; 2008 Feb; 46(4):625-33. PubMed ID: 18190281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries.
    Llibre JM; Revollo B; Vanegas S; Lopez-Nuñez JJ; Ornelas A; Marin JM; Santos JR; Marte P; Morera M; Zuluaga P; Tor J; Clotet B
    Scand J Infect Dis; 2013 Aug; 45(8):635-44. PubMed ID: 23547568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.
    Alvarez-Martínez MJ; Miró JM; Valls ME; Mas J; de la Bellacasa JP; Sued O; Solé M; Rivas PV; de Lazzari E; Benito N; García F; Agustí C; Wilson PE; Gatell JM; Jiménez de Anta MT; Meshnick SR; Moreno A
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):60-5. PubMed ID: 20727472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005).
    Kelley CF; Checkley W; Mannino DM; Franco-Paredes C; Del Rio C; Holguin F
    Chest; 2009 Jul; 136(1):190-197. PubMed ID: 19255292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The first one hundred AIDS cases in Hong Kong.
    Lee SS; Lo YC; Wong KH
    Chin Med J (Engl); 1996 Jan; 109(1):70-6. PubMed ID: 8758375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy.
    Urschel S; Ramos J; Mellado M; Giaquinto C; Verweel G; Schuster T; Niehues T; Belohradsky B; Wintergerst U;
    AIDS; 2005 Dec; 19(18):2103-8. PubMed ID: 16284459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia.
    Sleasman JW; Hemenway C; Klein AS; Barrett DJ
    Am J Dis Child; 1993 Jan; 147(1):30-4. PubMed ID: 8093422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.